Skip to main content

Sharecafe

Daily Special: Immutep, Litchfield Minerals, Golden Mile Resources, Invion

Australian shares retreat on weaker commodity prices and Wall Street volatility, while a surprise rise in unemployment reshapes interest rate expectations
The Australian sharemarket traded lower towards midday on Thursday, weighed down by falling commodity prices and continued volatility on Wall Street. The S&P/ASX 200 fell 86.5 points, or 0.98 per cent, to 8,735.3 at 12.05pm AEDT, with five of the 11 sectors trading lower. Mining stocks led declines as copper prices plunged 5 per cent and gold fell more than 3 per cent. BHP, Rio Tinto, Northern Star Resources and Evolution Mining weakened, while energy stocks also declined as Brent crude fell 2.5 per cent. The major banks traded lower, led by National Australia Bank.
Australian unemployment unexpectedly rose to 4.9 per cent in October from 4.7 per cent, with the economy shedding 43,500 jobs, prompting a sharp fall in the Australian dollar and bond yields as markets shifted towards expectations of an interest rate cut in early 2027. Overnight, the S&P 500 declined for a fifth consecutive session as Nvidia fell nearly 3 per cent, while the Nasdaq 100 recorded a modest gain. US Federal Reserve minutes indicated officials remained concerned about inflation and the potential need for further rate increases. In company news, A2 Milk, Nufarm and Challenger declined, while SkinKandy advanced following stronger revenue growth.
In small cap company news:
Immutep reports new sarcoma survival data and outlines revised clinical strategy
Immutep (ASX: IMM) has reported further results from its Phase II EFTISARC-NEO trial, with 81.1 per cent of 38 evaluable soft tissue sarcoma patients remaining disease-free at 12 months. New exploratory analysis presented at the Connective Tissue Oncology Society meeting showed a 95 per cent disease-free survival rate among patients with higher levels of tumour-infiltrating immune cells, compared with 64.9 per cent in those with lower levels. In a separate investor update, Immutep confirmed it is prioritising further development of eftilagimod alfa in soft tissue sarcoma and head and neck cancer, alongside its IMP761 autoimmune disease program. The company is targeting a potential registration-directed sarcoma trial in the second half of 2027, subject to regulatory, manufacturing and funding requirements. Its investigation into the discontinued TACTI-004 trial remains ongoing, with an update expected at its annual general meeting on 27 November. Click here to view the full announcement.
Litchfield Minerals identifies four copper-nickel exploration targets in Northern Territory
Litchfield Minerals (ASX: LMS) has identified four priority exploration areas at its Harts Range Project in the Northern Territory following geophysical surveys completed through BHP’s Xplor program. The magnetotelluric and gravity surveys covered approximately 1,100 square kilometres and identified conductive structures that could be associated with copper and nickel sulphide mineralisation. The results also identified a deeper conductor extending more than five kilometres below surface, potentially linked to geological structures capable of transporting mineral-bearing fluids. Litchfield has commenced field reconnaissance and plans further modelling and detailed surveys to refine potential drilling targets. The company cautioned that the anomalies could have alternative geological explanations, with further exploration required to confirm mineralisation.
 
Golden Mile Resources raises $950,000 for Arizona gold drilling
Golden Mile Resources (ASX: G88) has secured commitments to raise $950,000 through a share placement to fund exploration at its Aurora Gold Prospect in Arizona, United States. The placement will involve the issue of 190 million shares at half a cent each, with participating investors also receiving options subject to shareholder approval. Previous surface sampling at Aurora returned gold grades of up to 10.8 grams per tonne, identifying an exploration target extending approximately 800 metres along strike. Golden Mile plans to commence its maiden reverse circulation drilling program in January 2027, comprising 10 holes designed to test whether surface gold mineralisation continues at depth. The drilling remains subject to final permits and approvals.
Invion receives $503,000 R&D tax rebate to support cancer therapy development
Invion (ASX: IVX) has received approximately $503,000 in cash through the Australian Government’s Research and Development Tax Incentive program for the 2026 financial year. The rebate relates to eligible Australian research expenditure and provides additional non-dilutive funding for the company’s Photosoft photodynamic therapy platform and lead cancer treatment candidate, INV043. Invion is progressing plans for a Phase II skin cancer trial and a separate anogenital cancer study co-sponsored by the Peter MacCallum Cancer Centre. The company recently announced financing arrangements designed to cover up to approximately 85 per cent of future clinical trial costs. The latest rebate will support ongoing development activities as Invion advances its clinical pipeline.

Serving up fresh finance news, marker movers & expertise.
LinkedIn
Email
X

All Categories

Subscribe

get the latest